:  + 86-21-6100-2280
search
Our Service
Hu CD34 Hematopoietic Stem Cell Reconstitution Mouse Model

There is a major obstacle to the evaluation of new human immunotherapies due to a lack of experimental models with a fully functional human immune system. Therefore, the development of humanized experimental models is an unmet needed in immunotherapy research. As part of PharmaLegacy’s commitment to furthering immuno-oncology research, we have developed a humanized mouse model which harness the human immune system against human tumors.

We reconstitute immunocompromised mice with a human hematopoietic system via engraftment of human cord blood CD34+ cells. This humanized mice model provides highly predictive of patient response to novel immunotherapeutic agents.

6-1.jpg

Humanization (level of huCD45+ cells in peripheral blood)

6-2.jpg

1. Level of “humanization” (human CD45+ cells ratio) ranged between 40%-60%, with little variation between batches of CD34 HSC (hematopoietic stem cells) transplanted-animals.

6-3.jpg

2. Level of human T cells reconstitution in peripheral blood increased continuously post CD34 HSC transplantation .


CD34 models Validated with PD-1/PD-L1 Abs
PD-L1 high expressing human cancer lines

blob.png


PD1/PD-L1 Ab Test in HCC-827 Models

6-5.jpg

Immune checkpoint inhibitors PD-1 and PD-L1 Abs (lead molecules from local R&D collaborators) demonstrated significant inhibitory effects on the growth of HCC-827 human NSCLC cell line.

Ongoing PD-1/PDL-1 combo tests:

PD-1 + Her2; PD-1 + Tim3; PD-1 + EGFR; PD-1 + VEGF; PD-1 + CTLA4 and more …


CD34 models & Bi-specific Abs
Bi-specific Ab test in Raji model

Bi-specific Ab demonstrated significant inhibitory effects on the growth of Raji human Burkitt's lymphoma cell line subcutaneous inoculation.

6-6.jpg


Bi-specific Ab test in Raji model: Immunocyte profiling in tumor

6-7.jpg

With fully validated RA models and the state-of-art equipment, PharmaLegacy provides exceptional services for preclinical pharmacology studies of the drug candidates for RA treatment, including:


CD34 models & CAR-T

6-9.jpg


CD34 models & Oncolytic virus
Oncolytic Virus – direct tumor killing and OV-directed antitumor immune responses

6-10.jpg

Oncolytic virus was injected into the right tumor, the left untreated tumor was also associated with a significant reduction in tumor volume.

Demonstration of differential regulation of disease progression and clinical symptoms

Oncolytic Virus test in HCC827 model

6-11.jpg